Date | Compound | Laboratory | Indication | Type of Information |
---|---|---|---|---|
2012-11-08 | Adeno-associated viral vector encoding an inducible short hairpin RNA targeting claudin-5 (prior to administration of 17-dimethylaminoethylamino-17-demethocygeldanamycin) | Avena Therapeutics (Ireland) | retinitis pigmentosa |
Granting of the orphan status in the EU |
2012-12-26 | alisertib | Takeda Global Research and Development Centre (UK) | ovarian cancer | |
2012-12-26 | canakinumab | Novartis (Switzerland) | tumour necrosis factor receptor-associated periodic syndrome |
Granting of a patent |
2017-05-09 | dinutuximab beta | Apeiron Biologics (Austria)/EUSA Pharma (UK) | neuroblastoma | Granting of a Market Authorisation in the EU |
2012-11-08 | encapsulated human retinal pigment epithelial cell line transfected with plasmid vector expressing human ciliary neurotropic factor | Enpharma (UK) | macular telangiectasia type 2 |
Granting of the orphan status in the EU |
2012-12-26 | erdosteine | Rafifarm (Romania) | mercury toxicity | |
2012-12-26 | IL-12-secreting dendritic cells loaded with autologous tumour lysate | Activartis Biotech (Austria) | glioma |
Granting of a patent |
2012-12-26 | ixazomib | Takeda Global Research and Development Centre (UK) - Millennium Pharmaceuticals (USA - MA) | systemic light chain amyloidisis |
Granting of the orphan status in the EU |
2012-12-26 | melarsoprol | Pr. Peter Kennedy (UK) | African trypanosomiasis | |
2012-12-26 | milciclib maleate | Nerviano Medical Sciences (Italy) | malignant thymoma/thymic epithelial tumors |
Granting of the orphan status in the EU |
2012-12-26 | naloxone hydrochloride dihydrate | Winston Laboratories (UK) | cutaneous T-cell lymphoma | |
2015-08-28 | panobinostat | Novartis (Switzerland) | multiple myeloma |
Granting of a Market Authorisation in the EU |
2012-12-26 | recombinant human dyskerin | Advanced Medical Projects (Spain) | dyskeratosis congenita | |
2012-12-26 | synthetic double-stranded siRNA oligonucleotide directed against claudin-5 complexed with polyethyleneimine (prior to administration of doxorubicin) | Avena Therapeutics (Ireland) | glioma | |
2012-12-26 | tafamidis | Pfizer (USA - NY) | senile systemic amyloidosis |
Granting of the orphan status in the USA |
2012-12-26 | tralokinumab | MedImmune (USA - global biologics arm of AstraZeneca (UK) | idiopathic pulmonary fibrosis | |
2017-03-06 | ataluren - 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazole-3-yl]-benzoic acid | PTC Therapeutics (USA - NJ) | nonsense mutation Duchenne muscular dystrophy (nmDMD) | Acceptation for review of a NDA |
2016-12-16 | lomitapide | Aegerion Pharmaceuticals (USA - MA), a Novelion Therapeutics' subsidiary (Canada) | homozygous familial hypercholesterolemia (HoFH) | Product launch |
2013-01-02 | avanafil | Vivus (USA - CA) Auxilium Pharmaceuticals (USA - MA) | erectile dysfunction |
Granting of a Market Authorisation in the US |
2018-09-20 | enzalutamide | Medivation (USA - CA), now Pfizer (USA - NY) Astellas (Japan) |
|
Positive opinion for the granting of a Market Authorisation in the EU |
© 2024 Biopharmanalyses - Powered by Samacom+